#### **APPENDICIES**

#### Appendix A

# **Consent Form**

Title	A Double-Blind, Placeb	o Controlled, Randomised Phase II Trial of Probucol in Alzheimer's		
	Disease (PIA-Study): Th	ne Impact on Cogn	ition	
Protocol number	PIA-2020	PIA-2020		
Project sponsor	Curtin University			
Principal investigator	Associate Professor Rog	ger Clarnette		
Clinical contact person	Emily Corti	PHONE		
24-hour medical contact	Roger Clarnette	PHONE	EMAIL	

Note: All parties signing the consent section must date their own signature.

#### **Declaration by participant**

- I have read, or have had read to me, and I understand the General Information PICF as well as this Participant Information Sheet and Consent Form.
- I have had the opportunity to have a member of my family or another person present while the study is explained to me.
- I have had an opportunity to ask questions and I am satisfied with the answers I have received.
- I freely agree to participate in this study as described and understand that I am free to withdraw at any time during the study without affecting my future health care.
- I understand the purposes, procedures and risks of the research described in this Participant Information Sheet. Although I
  understand that the purpose of this study is to improve the quality of medical care, it has also been explained to me that my
  involvement may not be of any direct benefit to me.
- I understand that access may be required to my medical records for the purpose of this study as well as for quality assurance, auditing and in the event of a serious adverse event. I understand that such information will remain confidential.
- I understand that I will be randomised to either the Probucol (Lorelco™) or Placebo group, and that neither I nor the Study Doctor will know which group I am in.
- I understand and agree to my study partner providing information about my health to the Study Doctor.
- I consent to my local doctor being notified of my participation in this study and any clinically relevant information noted by the Study Doctor in the conduct of the study.
- I agree to adhere to the protocol requirements and restrictions as laid out in this Participant Information Sheet.
- I understand that I must use adequate contraception during the study. In the event of myself or my partner becoming pregnant, I must inform the Study Doctor immediately.
- I am 18 years of age and under 85 years of age.
- I understand that I will be given a signed copy of this document to keep.

Signature			Date	Time
Name of pa	rticipant (please print)	First, Middle Name or I	nitial, Last (must be as	s per photo ID)

#### **Declaration by trial doctor**

I have given a verbal explanation of the clinical trial, its procedures and risks and I believe that the participant has understood that explanation.

Signature		 Date	Time
Name of tria	al doctor (please print)		

#### Appendix B

# Consent Form for Continued Participation in the Event of Cognitive Decline

Title		A Double-Blind, Placebo Controlled, Randomised Phase II Trial of Probucol in		
	Alzheimer's Disease (PIA-Study): The Impac	t on Cognition		
Protocol number	PIA-2020			
Study Phase	Phase 2			
Global Sponsor	Curtin University			
Study Doctor				
Site contact person	Emily Corti	PHONE		
24	Associate Prof Roger Clarnette	EMAIL		
24-hour medical contact	PHONE			

Note: All parties signing the consent section must date their own signature.

## **Declaration by Participant**

- I have read, or have had read to me, and I understand the participant information and consent form.
- I have had the opportunity to have a member of my family or another person present while the study is explained to me.
- I have had an opportunity to ask questions and I am satisfied with the answers I have received.
- I freely agree to participate in this study as described and understand that I am free to withdraw at any time
  during the study without affecting my future health care.
- I understand that the Study Doctor has the right to withdraw me from the study at any point.
- I understand that I will be given a signed copy of this document to keep.

I consent to continue my participation in the study in the event that my memory and thinking skills decline during the study.

Signature	Signature		Date	Time
Name of participant (please print)				
		First Name, Middle Name or Initial, Last Name		

## Declaration by Study Doctor

I have given a verbal explanation of the study, its procedures and risks and I believe that the participant has understood that explanation.

Signature			Date	Time
Name of Stu	dy Doctor (please print)			

#### Appendix C

# Consent Form for the Use and Storage of Blood Samples for Future Research

Title	A Double-Blind, Placebo Controlled, Randomised Phase II Trial of Probucol in		
	Alzheimer's Disease (PIA-Study): The Impac	t on Cognition	
Protocol number	PIA-2020		
Study Phase	Phase 2		
Global Sponsor	Curtin University		
Study Doctor			
Site contact person	Emily Corti	0468 532 458	
24-hour medical contact	Associate Prof Roger Clarnette 0415 956 611	Roger.Clarnette@health.wa.gov.au	

Note: All parties signing the consent section must date their own signature.

#### **Declaration by Participant**

- I have read, or have had read to me, and I understand the participant information and consent form.
- I have had the opportunity to have a member of my family or another person present while the study is explained to me.
- I have had an opportunity to ask questions and I am satisfied with the answers I have received.
- I freely agree to participate in this study as described and understand that I am free to withdraw at any time during
  the study without affecting my future health care.
- I understand the purposes, procedures and risks of the research described in this Participant Information Sheet.
   Although I understand that the purpose of this study is to improve the quality of medical care, it has also been explained to me that my involvement may not be of any direct benefit to me.
- I consent to my local doctor being notified of my participation in this study and any clinically relevant information noted by the Study Doctor in the conduct of the study.
- I agree to adhere to the protocol requirements and restrictions as laid out in the main Participant Information Sheet and this Participant Information Sheet.
- I understand that I must use adequate contraception during the study. In the event of myself or my partner becoming
  pregnant, I must inform the Study Doctor immediately.
- I am over 18 years of age, or younger than 85 years of age.
- I understand that I will be given a signed copy of this document to keep.

I consent to have additional blood samples taken for future research purposes in Alzheimer's Disease and for blood samples taken from this study to be stored and used for future research purposes. I also consent to being contacted in the future about providing additional blood samples for future Alzheimer's related projects

Signature			Date	Time
Name of par	rticipant (please print)	First Name, Middle Nam	ne or Initial, Last Name	

## **Declaration by Study Doctor**

I have given a verbal explanation of the study, its procedures and risks and I believe that the participant has understood that explanation.

Signature			Date	Time
Name of Stu	dy Doctor (please print)			

### Appendix D

### **Consent Form**

Title	A Double-Blind, Placebo Controlled, Randomised Phase II Trial of Probucol in Alzheimer's Disease (PIA-Study): The Impact on Cognition				
Protocol number	PIA-2020				
Project sponsor	Curtin University				
Principal investigator	Associate Professor Rog	essor Roger Clarnette			
Clinical contact person	Emily Corti	PHONE			
24-hour medical contact	Roger Clarnette	PHONE EMAIL			

Note: All parties signing the consent section must date their own signature.

## Declaration by study partner

- I have read, or have had read to me, and I understand the General Information PICF as well as this Partner Information Sheet and Consent Form.
- I agree to the above requirement of study partners, as set out in the Participant Information sheet and Consent form. I also acknowledge that at no time am I, as the study partner, receiving the treatment.
- I have had an opportunity to ask questions and I am satisfied with the answers I have received.
- I freely agree to participate in this study as described and understand that I am free to withdraw at any time
  during the study without affecting my future health care.
- I freely agree to meet the minimum study requirements which includes; attending one screening visit, completing a questionnaire at the start, at 6 months, and at the end of the study, and be available by phone monthly, as needed.
- I understand that by consenting to the minimum study requirements, the study participant may continue through the screening phase of the study and, if eligible, will receive the study medication.
- I understand that I will be given a signed copy of this document to keep.

Signature			Date	Time
Name of stu	dy partner (please print)	First, Middle Name or I	nitial, Last (must be as	s per photo ID)

## Declaration by trial doctor

I have given a verbal explanation of the clinical trial, its procedures and risks and I believe that the study partner has understood that explanation.

Signature		 Date	Time
Name of tria	al doctor (please print)		